Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02025023 · ClinicalTrials.gov registry record · Phase 3

Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

A Phase 3 study of Chalazion, sponsored by University of Washington.

Recruiting
Registry status
Phase 3
Development phase
120
Enrollment target
1
Study location

NCT02025023 is a Phase 3 study of Chalazion that is actively recruiting participants, run by University of Washington. The registered enrollment target is 120 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02025023, a Phase 3 study of Chalazion, is actively recruiting participants, sponsored by University of Washington.

RECRUITING
Registry status
Phase 3
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

Local injection of 5-fluorouracil into a chalazion (stye) is as effective as local injection of triamcinolone (steroid) and incision and curettage for treatment of chalazia.

Conditions Studied

Interventions

  • DRUG 5-fluorouracil Injection
  • DRUG Triamcinolone Acetonide
  • PROCEDURE Incision and Curettage
  • DRUG Triamcinolone Acetonide/5-fluorouracil mixture

Study Locations (1)

Washington

  • University of Washington Eye Institute at Harborview - Seattle

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2013-12
Est. Completion 2026-07
Phase Phase 3

Sponsor

University of Washington

1,048 total trials

What the Registry Record Tells You About NCT02025023

The ClinicalTrials.gov registry entry for NCT02025023 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chalazion appearing as the primary indexed condition, and to 4 interventions - of which 5-fluorouracil Injection is the first listed.

NCT02025023 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT02025023 about?

NCT02025023 is a clinical study titled "Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study". Local injection of 5-fluorouracil into a chalazion (stye) is as effective as local injection of triamcinolone (steroid) and incision and curettage for treatment of chalazia.

What is the current status of trial NCT02025023?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2013-12. Estimated completion is 2026-07.

What conditions does trial NCT02025023 study?

This clinical trial studies the following conditions: Chalazion.

What interventions are being tested in trial NCT02025023?

The interventions under investigation include: 5-fluorouracil Injection (DRUG), Triamcinolone Acetonide (DRUG), Incision and Curettage (PROCEDURE), Triamcinolone Acetonide/5-fluorouracil mixture (DRUG).

Who is sponsoring clinical trial NCT02025023?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02025023 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chalazion

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.